China Top 10 Freeze Rabies Prophylaxis Vaccine Brands

May 04, 2024

Freeze Rabies Prophylaxis Vaccine is a crucial tool in preventing rabies, a deadly viral disease transmitted through animal bites. This vaccine is designed to provide immediate protection against rabies infection and is recommended for individuals at risk of exposure to the virus, such as veterinarians, animal handlers, and travelers to rabies-endemic regions. It is essential for public health efforts to control and eliminate rabies worldwide.

Rabipur
Rabies Vaccine BP
Changchun Zhuoyi Biological Co., Ltd
Verorab

Rabipur

Establishment time : 1984

website : www.rabipur.com

Main Product : Rabies vaccine

Company Profile

Rabipur is a renowned pharmaceutical company specializing in the production of rabies vaccines. Established in 1984, Rabipur has grown to become a global leader in providing high-quality vaccines to prevent rabies infections. With a large market presence and a strong competitive position, Rabipur continues to innovate and improve its products to meet the growing demand for Rabies Prevention worldwide.

Rabies Vaccine BP

Establishment time : 1974

website : www.rabiesvaccinebp.com

Main Product : Rabies vaccine

Company Profile

Rabies Vaccine BP is a leading manufacturer of rabies vaccines, established in 1974. We specialize in producing high-quality vaccines to protect against rabies and serve markets worldwide. With a medium-sized company, we face strong competition in the vaccine industry but strive to maintain our reputation for excellence and reliability. Visit our website at www.rabiesvaccinebp.com for more information.

Changchun Zhuoyi Biological Co., Ltd

Establishment time : 2005

website : www1.zhuoyi-bio.com

Main Product : Human Rabies Vaccine,Rabies Prevention ,Freeze-dried Human Rabies Vaccine ,Rabies Vaccine,Human Rabies Vaccination,Human Rabies Vaccine and Infant

Company Profile

Changchun Zhuoyi Biological Co., Ltd., located in Shuangyang Economic Development Zone of Changchun City, is a key vaccine manufacturer invested by Zhejiang SelCorning Biotechnology Co., Ltd. in Jilin Province, and a vice chairman unit of Zhejiang Chamber of Commerce in Jilin Province. The company was founded on January 27, 2005. Mr. Feng Xingfu, chairman and general manager of the company, graduated from the Department of Biology, University of Science and Technology of China, and has been engaged in the marketing and enterprise management of biological products since the 1980s. The company has a registered capital of one hundred and one million six hundred and ninety-two thousand seven hundred and eighty-four yuan, covers an area of 41600 square meters, and has the leading vaccine research and development and production capacity in China. Changchun Zhuoyi Biological Co., Ltd. is a new vaccine manufacturer integrating R&D, production and sales. At present, the biological products approved by the company are mainly Rabies Vaccine (Vero cell) for Human Use, Freeze-dried. The company successfully passed the two in one inspection at the end of 2016 and obtained the registration approval and GMP certificate, which was officially put into production in January 2017. The company's existing production workshop covers an area of about 5700 square meters, with a cumulative investment of 400 million yuan. At present, the maximum annual output is 1 million people. The second phase workshop has been completed at the end of 2018, and will be officially produced in 2020. By then, the production capacity can reach 4 million people. The company has nearly 2000 square meters of pilot scale research workshop, advanced equipment such as bioreactor, ultrafiltration system, AKTA purification workstation, fluorescence microscope, etc., which are used for virus culture, improvement of purification system and identification of recombinant protein. The company has maintained close scientific research cooperation with many scientific research institutions at home and abroad. At present, the company is developing a serum rabies vaccine and a broad-spectrum human papillomavirus vaccine jointly developed with the Institute of Basic Medicine of the Chinese Academy of Medical Sciences. It is planned to cooperate with Murdoch Children's Research Institute in Australia to develop the round vaccine project. At the same time, the company also actively explores the path of internationalization. At present, the company has started to register in the Philippines, Pakistan, Cambodia, Bangladesh, Mongolia, Uzbekistan and other countries. It is estimated that the export of finished products in some markets will be realized by 2020. The company's technical cooperation project with Australia is one of the company's many international cooperation projects. The company always adheres to the concept of "standardized management, quality first", and adheres to the core values of "honesty, diligence, innovation, preciseness, learning and happiness", so as to provide high-quality vaccine products to serve the health of the people.

Verorab

Establishment time : Verorab is a rabies vaccine produced by Sanofi Pasteur, a global pharmaceutical company with a long history of vaccine development.

website :

Main Product : Verorab is one of the key products in Sanofi Pasteur's portfolio, designed to prevent rabies infection in individuals at risk.

Company Profile

Overall, Sanofi Pasteur and its Verorab vaccine play a crucial role in preventing rabies infections and protecting public health globally.

Author:

Mr. Simba Li

E-mail:

lixuejian@zy-bio.cn

Phone/WhatsApp:

+86 18946525326